We are committed to developing and bringing to market next generation antitoxins to make treatment safe, effective, and available around the world.
The first market we are addressing is the large ($1B) and highly underserved snake antivenom market.
Conventional antivenom is made the same way it was made over a century ago! Venom milked from a snake is repeatedly injected into a horse which builds immunity and the antibodies are eventually purified from the blood of the horse.
This results in conventional antivenom with the following issues:
- Low potency- less than 5% of antibodies are specific to venom toxins
- Side effects- horse antibodies create dangerous side effects in human patients
- Unreliable- difficult production process requires animals and has low batch-to-batch consistency
- Limited treatment- works only for a small range of snake species
Here at Venomyx we believe it's time for a change.
Watch CEO Dan Dempsey pitch at IndieBio Demo Day